Aeglea BioTherapeutics (NASDAQ:AGLE) Rating Lowered to Market Perform at Lifesci Capital

Lifesci Capital cut shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) from an outperform rating to a market perform rating in a research report sent to investors on Wednesday morning, MarketBeat reports. A number of other research analysts have also issued reports on the company. HC Wainwright reissued a neutral rating and issued a $1.00 […]

Related Keywords

Aeglea Biotherapeutics ,Charles Schwab Investment Management Inc ,Aeglea Biotherapeutics Company Profile ,Nantahala Capital Management ,Aeglea Biotherapeutics Inc ,Wells Fargo Company ,Acadian Asset Management ,Lifesci Capital ,Get Rating ,Wells Fargo ,Asset Management ,Capital Management ,Schwab Investment Management ,Street Corp ,Rock Springs Capital Management ,Springs Capital Management ,Nasdaq Agle ,Beagle ,Medical ,Downgrade ,